MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals

The Heart Protection Study is one of the largest and most influential statin trials ever conducted, and it answered a pivotal question: does lowering cholesterol help even patients whose cholesterol is not high to begin with?

In over 20,000 high-risk individuals, simvastatin reduced all-cause mortality by 12 percent, coronary deaths by 18 percent, and major vascular events by about a quarter — and crucially, the benefit was consistent regardless of baseline cholesterol, including patients whose LDL was already “normal” or low. The benefit tracked the patient’s baseline risk, not their starting cholesterol number.

This finding reframed statin therapy. It shifted the question from “is your cholesterol high?” to “is your cardiovascular risk high?” — establishing that high-risk patients benefit from LDL lowering across the cholesterol spectrum, a principle embedded in every modern guideline.

We rate the evidence very strong. A massive, rigorous, placebo-controlled randomized trial, it is a cornerstone of preventive cardiology and a key pillar of the “treat risk, not just numbers” approach.